J&J's embattled Invokana gets a boost as FDA expands label
For Johnson & Johnson’s ailing diabetes drug Invokana, the expansion of its label could be the antidote that revives sales.
On Monday, the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
